Borealis is deeply rooted in the Dartmouth College community and uniquely committed to partnering with Dartmouth researchers, students and alumni around the world in building businesses to commercialize their innovations.
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Boehringer Ingelheim (BI). Under the terms of the agreement, Adimab will use [...]
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2017 it entered into agreements with seven new companies. In addition, Adimab announced the [...]
Eli Lilly likes what it sees in Adimab's antibody R&D platform, opting to roll it out at sites in San Diego and New York to help its antibody discovery and optimization activities. The big pharma [...]
Avitide, Inc., the industry leader in the discovery, and manufacture of exclusive biopharmaceutical affinity purification solutions, today announced the closing of a Series E financing. Sands Capital Ventures, LLC led the financing round with participation [...]
"I’ve worked with Borealis on multiple startups, including Adimab, Avitide, and Compass, and can attest to the firm’s crucial role in helping Dartmouth entrepreneurs build their companies as the trusted and local early-stage investor. The Borealis team are dedicated and thoughtful partners who align themselves with founders and support their vision."
COO and Co-Founder, Compass
Founder, Adimab, Avitide
We’re always interested in engaging with inventors, creators, and entrepreneurs to help develop ideas and realize visions.